Skip to main content
SpringerLink
Log in

Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis

  • Pulmonary Hypertension
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Background

Patients with pulmonary arterial hypertension (PAH) and distal chronic thromboembolic pulmonary hypertension (CTEPH) who still reveal risk factors of worse prognosis on double combination therapy may benefit from add-on therapy with the novel oral selective prostacyclin receptor agonist selexipag.

Methods

We reviewed all patients with PAH/distal CTEPH in the Zurich cohort who received selexipag as add-on to oral combination therapy and retrieved New York Heart Association (NYHA) functional class, 6-min walk distance (6MWD), NT-pro-BNP, quality of life questionnaires (CAMPHOR and EuroQoL), tricuspid pressure gradient (TPG) by echocardiography and cardiopulmonary exercise test parameters (power output and oxygen uptake).

Results

Twenty-three patients with PAH/CTEPH (20/3), 14 females, median (quartiles) age 56 (46; 66) years received an oral triple therapy containing selexipag at a median dose of 2000 (1600; 3100) mcg during 221 (113; 359) days. The following parameters were stabilized from baseline to last FU: 6MWD (440 (420; 490) to 464 (420; 526) m), NYHA class (three to two), NT-pro-BNP (326 (167; 1725) to 568 (135; 1856)  ng/l), TPG, power output, and oxygen uptake. Quality of life reflected by the CAMPHOR and EuroQoL improved.

Conclusions

Early initiation of triple oral combination therapy including selexipag in PAH/CTEPH with intermediate risk factor profile may help to stabilize functional class, exercise performance, and pulmonary hemodynamics in a real-life setting and potentially improves quality of life. Whether these beneficial effects can be truly attributed to the addition of selexipag should be addressed in future randomized controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 37(1):67–119

    Google Scholar 

  2. Wilkens H, Konstantinides S, Lang I, Bunck AC, Gerges M, Gerhardt F et al (2016) Chronic thromboembolic pulmonary hypertension: recommendations of the Cologne Consensus Conference 2016. Dtsch Med Wochenschr 141(S01):S62–S69

    CAS  PubMed  Google Scholar 

  3. Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M (2006) Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 130(3):841–846

    Article  PubMed  Google Scholar 

  4. Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R et al (2006) Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 28(4):808–815

    Article  CAS  PubMed  Google Scholar 

  5. Cannon JE, Pepke-Zaba J (2013) Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs? Semin Respir Crit Care Med 34(5):620–626

    Article  CAS  PubMed  Google Scholar 

  6. Voelkel NF, Cool C (2004) Pathology of pulmonary hypertension. Cardiol Clin 22(3):343–351

    Article  PubMed  Google Scholar 

  7. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV et al (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373(9):834–844

    Article  CAS  PubMed  Google Scholar 

  8. Galie N, Muller K, Scalise AV, Grunig E (2015) PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 45(5):1314–1322

    Article  CAS  PubMed  Google Scholar 

  9. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369(9):809–818

    Article  CAS  PubMed  Google Scholar 

  10. Bartenstein P, Saxer S, Appenzeller P, Lichtblau M, Schwarz EI, Ulrich S (2018) Risk factor profiles achieved with medical therapy in prevalent patients with pulmonary arterial and distal chronic thromboembolic pulmonary hypertension. Respiration 96(1):127–137

    Article  PubMed  Google Scholar 

  11. Sitbon O, Sattler C, Bertoletti L, Savale L, Cottin V, Jais X et al (2016) Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 47(6):1727–1736

    Article  CAS  PubMed  Google Scholar 

  12. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340

    Article  CAS  PubMed  Google Scholar 

  13. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N et al (2012) Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40(4):874–880

    Article  CAS  PubMed  Google Scholar 

  14. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533

    Article  CAS  PubMed  Google Scholar 

  15. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N et al (2017) Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 50(2):1602493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mueller-Mottet S, Stricker H, Domenighetti G, Azzola A, Geiser T, Schwerzmann M et al (2015) Long-term data from the Swiss pulmonary hypertension registry. Respiration. 89(2):127–140

    Article  PubMed  Google Scholar 

  17. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D et al (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981

    Article  PubMed  Google Scholar 

  18. Evangelista A, Flachskampf F, Lancellotti P, Badano L, Aguilar R, Monaghan M et al (2008) European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. Eur J Echocardiogr 9(4):438–448

    Article  PubMed  Google Scholar 

  19. Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S et al (2017) A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 39(47):4175–4181

    Article  Google Scholar 

  20. Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G et al (2017) Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 50(2):1700889

    Article  CAS  PubMed  Google Scholar 

  21. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N et al (2017) Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 50(2):1700740

    Article  CAS  PubMed  Google Scholar 

  22. Coghlan JG, Channick R, Chin K, Di Scala L, Galie N, Ghofrani HA et al (2018) Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 18(1):37–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S et al (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D73–D81

    Article  PubMed  Google Scholar 

  24. Deboeck G, Scoditti C, Huez S, Vachiery JL, Lamotte M, Sharples L et al (2012) Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 40(6):1410–1419

    Article  PubMed  Google Scholar 

  25. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J (2006) The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 15(1):103–115

    Article  CAS  PubMed  Google Scholar 

  26. Cima K, Twiss J, Speich R, McKenna SP, Grunig E, Kahler CM et al (2012) The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR). Health Qual Life Outcomes 10(1):110

    Article  PubMed  PubMed Central  Google Scholar 

  27. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J et al (2008) The responsiveness and validity of the CAMPHOR utility index. Eur Respir J 32(6):1513–1519

    Article  CAS  PubMed  Google Scholar 

  28. Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53–72

    Article  CAS  Google Scholar 

Download references

Funding

The study was funded by grants for the Zurich PH cohort from the Zurich Lung.

Author information

Authors and Affiliations

  1. Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland

    Charlotte Berlier, Esther I. Schwarz, Stéphanie Saxer, Mona Lichtblau & Silvia Ulrich

  2. Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland

    Silvia Ulrich

Authors
  1. Charlotte Berlier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esther I. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stéphanie Saxer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mona Lichtblau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvia Ulrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvia Ulrich.

Ethics declarations

Conflict of interest

None of the authors declares any conflict of interest in relation to the present work. SU received grant money from the Swiss National Science Foundation, Zurich Lung, Actelion SA, Bayer SA, Orpha Swiss. SU; EIS, SS, ML and CB received travel support and lecture fees from Actelion SA, Bayer SA, MSD SA and Orpha Swiss.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective cohort study complied with the ethical laws in Switzerland and all patients have signed informed consent for the Zurich PH cohort study (KEK 2014-0214).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berlier, C., Schwarz, E.I., Saxer, S. et al. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis. Lung 197, 353–360 (2019). https://doi.org/10.1007/s00408-019-00222-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-019-00222-7

Keywords

Search

Navigation